

Eliem Therapeutics, Inc.  
23515 NE Novelty Hill Road, Suite B221 #125  
Redmond, WA 98053

August 5, 2021

**Via EDGAR Submission**

Securities and Exchange Commission  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549

Attn: Sasha Parish  
Vanessa Robertson  
Dillon Hagus  
Jeffrey Gabor

Re: Eliem Therapeutics, Inc.  
Registration Statement on Form S-1, as amended (File No. 333-257980)  
Withdrawal of Request for Acceleration of Effective Date

Ladies and Gentlemen:

Reference is made to the several letters, each filed as correspondence via EDGAR on August 3, 2021, in which both we and the several underwriters requested the acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-257980) for August 5, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such registration statement be declared effective at this time and we hereby formally withdraw both our and the underwriters' requests for acceleration of the effective date.

Very truly yours,

Eliem Therapeutics, Inc.

/s/ Robert W. Azelby

By: Robert W. Azelby

Title: Chief Executive Officer

cc: Alan Hambelton, Cooley LLP  
Julia Stark, Cooley LLP  
Brian Cuneo, Latham & Watkins LLP  
Phillip Stoup, Latham & Watkins LLP